JP2010536396A - タンパク質力価を増加させる方法 - Google Patents

タンパク質力価を増加させる方法 Download PDF

Info

Publication number
JP2010536396A
JP2010536396A JP2010522371A JP2010522371A JP2010536396A JP 2010536396 A JP2010536396 A JP 2010536396A JP 2010522371 A JP2010522371 A JP 2010522371A JP 2010522371 A JP2010522371 A JP 2010522371A JP 2010536396 A JP2010536396 A JP 2010536396A
Authority
JP
Japan
Prior art keywords
protein
antibody
cells
cell
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010522371A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536396A5 (https=
Inventor
ドロテー アムブロジウス
バーバラ エネンケル
クリシュティアン エッカーマン
Original Assignee
ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト filed Critical ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト
Publication of JP2010536396A publication Critical patent/JP2010536396A/ja
Publication of JP2010536396A5 publication Critical patent/JP2010536396A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2010522371A 2007-08-29 2008-08-28 タンパク質力価を増加させる方法 Pending JP2010536396A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07115227A EP2031064A1 (de) 2007-08-29 2007-08-29 Verfahren zur Steigerung von Proteintitern
PCT/EP2008/061310 WO2009027471A1 (de) 2007-08-29 2008-08-28 Verfahren zur steigerung von proteintitern

Publications (2)

Publication Number Publication Date
JP2010536396A true JP2010536396A (ja) 2010-12-02
JP2010536396A5 JP2010536396A5 (https=) 2011-10-13

Family

ID=39107125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010522371A Pending JP2010536396A (ja) 2007-08-29 2008-08-28 タンパク質力価を増加させる方法

Country Status (6)

Country Link
US (1) US20100297697A1 (https=)
EP (2) EP2031064A1 (https=)
JP (1) JP2010536396A (https=)
KR (1) KR20100046219A (https=)
CA (1) CA2696809A1 (https=)
WO (1) WO2009027471A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014526884A (ja) * 2011-07-06 2014-10-09 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
JP2016512508A (ja) * 2013-03-12 2016-04-28 バイオコン・リミテッド 融合免疫調節タンパク質及びその生産方法
JP2018528214A (ja) * 2015-09-01 2018-09-27 オンコクール・エムエル・ゲーエムベーハー コイルドコイルコネクタ
JP2020141710A (ja) * 2011-07-06 2020-09-10 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
JP2021519754A (ja) * 2018-03-30 2021-08-12 アムジエン・インコーポレーテツド Ｃ末端抗体改変体

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
EP1878747A1 (en) * 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
KR101680906B1 (ko) * 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
TW201634479A (zh) 2007-12-05 2016-10-01 中外製藥股份有限公司 抗ｎｒ１０抗體及其應用
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
EP2826789A1 (en) 2009-03-19 2015-01-21 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
EP2455403A1 (en) * 2010-11-23 2012-05-23 Pierre Fabre Medicament Homogeneous humanized antibodies against JAM-A that inhibit proliferation
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
KR101591671B1 (ko) * 2011-04-29 2016-02-04 바이오콘 리서치 리미티드 항체의 이질성을 감소시키는 방법 및 그 항체의 제조방법
CN103717729B (zh) 2011-07-08 2017-11-21 动量制药公司 细胞培养方法
RS63930B1 (sr) 2011-10-28 2023-02-28 Prothena Biosciences Ltd Humanizovana antitela koja prepoznaju alfa-sinuklein
DK2807188T3 (da) 2012-01-27 2019-10-07 Prothena Biosciences Ltd Humaniserede antistoffer, der genkender alpha-synuclein
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
DK2841589T3 (en) * 2012-04-23 2019-01-07 Dsm Ip Assets Bv PROCEDURE FOR EXPRESSION OF POLYPEPTIDES
PL3489254T3 (pl) 2012-04-30 2023-01-30 Biocon Limited Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015004633A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize islet-amyloid polypeptide (iapp)
US9850302B2 (en) 2013-07-12 2017-12-26 Prothena Biosciences Limited Antibodies that recognize IAPP
ES2881306T3 (es) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Método para la producción de heteromultímeros de polipéptidos
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
JP2017501848A (ja) 2013-11-19 2017-01-19 プロセナ バイオサイエンシーズ リミテッド 便秘症状からのレビー小体病の免疫療法のモニター
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
KR20160131082A (ko) 2014-03-12 2016-11-15 프로테나 바이오사이언시즈 리미티드 Lg1-3에 특이적인 항-라미닌4 항체
JP2017514458A (ja) 2014-03-12 2017-06-08 プロセナ バイオサイエンシーズ リミテッド Ｌｇ４−５に対して特異的な抗−ラミニン４抗体
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
TWI769570B (zh) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI718121B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
CA2972393A1 (en) 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
EP3350226A2 (en) 2015-09-16 2018-07-25 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
MX2018013386A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
MY198194A (en) 2016-05-02 2023-08-09 Prothena Biosciences Ltd Antibodies Recognizing Tau
PT3452507T (pt) 2016-05-02 2022-12-20 Prothena Biosciences Ltd Imunoterapia anti-tau
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2018007924A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7016470B2 (ja) 2016-07-02 2022-02-07 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
WO2018007922A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
WO2019064053A1 (en) 2017-09-28 2019-04-04 Prothena Biosciences Limited DOSAGE REGIMES FOR THE TREATMENT OF SYNUCLEINOPATHIES
AU2018345807B2 (en) 2017-10-06 2025-02-06 Novo Nordisk A/S Methods of detecting transthyretin
PE20211453A1 (es) 2017-11-29 2021-08-05 Prothena Biosciences Ltd Formulacion liofilizada de un anticuerpo monoclonal contra transtirretina
CN112119090B (zh) 2018-03-15 2023-01-13 中外制药株式会社 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
CU24781B1 (es) 2018-11-08 2026-02-09 Prothena Biosciences Ltd Anticuerpos humanizados que reconocen tau
EA202190986A1 (ru) 2018-11-26 2021-12-14 Фоти Севен, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К c-Kit
JP7630834B2 (ja) 2019-03-03 2025-02-18 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
AR119303A1 (es) 2019-07-01 2021-12-09 Eisai R&D Man Co Ltd Anticuerpo anti-epha4 humano
EP4159236A4 (en) 2020-05-29 2024-08-21 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation
BR112022026508A2 (pt) 2020-06-24 2023-03-07 Prothena Biosciences Ltd Anticorpos que reconhecem sortilina
CA3195085A1 (en) 2020-12-24 2022-06-30 Eisai R&D Management Co., Ltd. Therapeutic pharmaceutical composition for amyotrophic lateral sclerosis
KR20230123923A (ko) 2020-12-24 2023-08-24 에자이 알앤드디 매니지먼트 가부시키가이샤 항-EphA4 항체
MX2024005057A (es) 2021-11-11 2024-05-10 Eisai R&D Man Co Ltd Anticuerpo de receptor 4 de efrina tipo a (anti-epha4).
TW202530246A (zh) 2023-09-15 2025-08-01 愛爾蘭商歐賽爾普羅希那有限公司 細胞穿透劑及其用途
WO2025059486A1 (en) 2023-09-15 2025-03-20 Prothena Biosciences Limited Anti-tdp-43 antibodies and uses thereof
WO2025059491A2 (en) 2023-09-15 2025-03-20 Prothena Platform Technologies Limited Methods, compositions, and kits including cell-penetrating agents
AR133834A1 (es) 2023-09-15 2025-11-05 Prothena Biosciences Ltd Agentes de penetración célular y sus usos

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02163096A (ja) * 1988-09-28 1990-06-22 Eli Lilly & Co モノクローナル抗体の不均質性を減少させる方法
JP2004536580A (ja) * 2001-04-13 2004-12-09 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｖｌａ−１に対する抗体
WO2005000892A2 (en) * 2003-06-12 2005-01-06 Eli Lilly And Company Glp-1 analog fusion plroteins
WO2006068910A1 (en) * 2004-12-22 2006-06-29 Eli Lilly And Company Glp-1 analog fusion protein formulations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
CN104072614B (zh) * 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02163096A (ja) * 1988-09-28 1990-06-22 Eli Lilly & Co モノクローナル抗体の不均質性を減少させる方法
JP2004536580A (ja) * 2001-04-13 2004-12-09 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｖｌａ−１に対する抗体
WO2005000892A2 (en) * 2003-06-12 2005-01-06 Eli Lilly And Company Glp-1 analog fusion plroteins
WO2006068910A1 (en) * 2004-12-22 2006-06-29 Eli Lilly And Company Glp-1 analog fusion protein formulations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6013026613; ＰＡＲＡＭＰＡＬＬＩ，　Ａ．　ｅｔ　ａｌ．: '"Ｄｅｖｅｌｏｐｅｍｅｎｔ　ｏｆ　ｓｅｒｕｍ-ｆｒｅｅ　ｍｅｄｉａ　ｉｎ　ＣＨＯ-ＤＧ４４　ｃｅｌｌｓ　ｕｓｉｎｇ　ａ　ｃｅｎｔｒａｌ　ｃｏｍｐｏｓｉｔｅ　ｓｔａｔｉｓｔｉｃａｌ　ｄｅｓｉｇｎ．"' ＣＹＴＯＴＥＣＨＮＯＬＯＧＹ Ｖｏｌ．５４，　Ｎｏ．１, 200705, Ｐ．５７-６８ *
JPN6013026616; ＫＡＮＤＡ，　Ｙ．　ｅｔ　ａｌ．: '"Ｅｓｔａｂｌｉｓｈｍｅｎｔ　ｏｆ　ａ　ＧＤＰ-ｍａｎｎｏｓｅ　４，６-ｄｅｈｙｄｒａｔａｓｅ　（ＧＭＤ）　ｋｎｏｃｋｏｕｔ　ｈｏｓｔ　ｃｅｌｌ　ｌｉｎｅ：　ａ　ｎｅｗ　ｓｔｒａｔｅｇｙ　ｆｏｒ　ｇｅ' ＪＯＵＲＮＡＬ　ＯＦ　ＢＩＯＴＥＣＨＮＯＬＯＧＹ Ｖｏｌ．１３０，　Ｎｏ．３, 20070630, Ｐ．３００-３１０ *
JPN7013002069; ＴＡＫＡＩ，　Ｔ．　ｅｔ　ａｌ．: '"Ｅｘｐｒｅｓｓｉｏｎ　ｏｆ　ｈｕｍａｎｉｚｅｄ　Ｆａｂ　ｆｒａｇｍｅｎｔｓ　ｔｈａｔ　ｒｅｃｏｇｎｉｚｅ　ｔｈｅ　ＩｇＥ-ｂｉｎｄｉｎｇ　ｄｏｍａｉｎ　ｏｆ　ｈｕｍａｎ　Ｆｃ（ｅｐｓｉｌｏｎ）ＲＩａ' ＪＯＵＲＮＡＬ　ＯＦ　ＢＩＯＣＨＥＭＩＳＴＲＹ Ｖｏｌ．１２９，　Ｎｏ．１, 200101, Ｐ．５-１２ *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019000116A (ja) * 2011-07-06 2019-01-10 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
JP2020141710A (ja) * 2011-07-06 2020-09-10 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
JP2014526884A (ja) * 2011-07-06 2014-10-09 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
JP2016512508A (ja) * 2013-03-12 2016-04-28 バイオコン・リミテッド 融合免疫調節タンパク質及びその生産方法
JP2019010111A (ja) * 2013-03-12 2019-01-24 バイオコン・リミテッド 融合免疫調節タンパク質及びその生産方法
US11090381B2 (en) 2015-09-01 2021-08-17 Oncoqr Ml Gmbh Coiled-coil connector
JP2018528214A (ja) * 2015-09-01 2018-09-27 オンコクール・エムエル・ゲーエムベーハー コイルドコイルコネクタ
JP2021519754A (ja) * 2018-03-30 2021-08-12 アムジエン・インコーポレーテツド Ｃ末端抗体改変体
JP7405764B2 (ja) 2018-03-30 2023-12-26 アムジエン・インコーポレーテツド Ｃ末端抗体改変体
US11858983B2 (en) 2018-03-30 2024-01-02 Amgen Inc. C-terminal anti-sclerostin antibody variants
JP2024037881A (ja) * 2018-03-30 2024-03-19 アムジエン・インコーポレーテツド Ｃ末端抗体改変体
JP7747715B2 (ja) 2018-03-30 2025-10-01 アムジエン・インコーポレーテツド Ｃ末端抗体改変体
US12570734B2 (en) 2018-03-30 2026-03-10 Amgen Inc. C-terminal anti-sclerostin antibody variants

Also Published As

Publication number Publication date
CA2696809A1 (en) 2009-03-05
EP2195431A1 (de) 2010-06-16
KR20100046219A (ko) 2010-05-06
EP2031064A1 (de) 2009-03-04
US20100297697A1 (en) 2010-11-25
WO2009027471A1 (de) 2009-03-05

Similar Documents

Publication Publication Date Title
JP2010536396A (ja) タンパク質力価を増加させる方法
JP5481478B2 (ja) 新規調節エレメント
US9243053B2 (en) Heterologous intron within an immunoglobulin domain
EP2938728B1 (en) Artificial introns
US20140248665A1 (en) Novel intron sequences
EP2938726B1 (en) Heterologous intron within a signal peptide
JP7826509B2 (ja) 選択マーカーとしての新規グルタミン合成酵素変異体
JP2025510718A (ja) 哺乳動物細胞における選択マーカーとしての細菌グルタミン合成酵素
US20110014624A1 (en) Methods For Identifying Cells Suitable For Large-Scale Production of Recombinant Proteins
HK1156663B (en) Novel regulatory elements

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110829

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131105